VERLYX PHARMA ANNOUNCES NEW DATA ON VLX103 TO BE PRESENTED AT THE AASLD 2016 ANNUAL LIVER MEETING, BOSTON, NOVEMBER 11-15.

Learn More >

verlyx-poster-distinction

Verlyx Pharma receives U.S. patent for its lead product VLX103 for the treatment of liver diseases or conditions.

Learn More >

verlyx-us-patent

VLX103, a first-in-class hepatoselective LPS neutralizer
for the treatment of liver diseases.

Learn More >

OE_SiteWeb_BulleImage_Hommebleu